(68 days)
Not Found
Not Found
No
The device description details a traditional immunoassay based on antibody reactions and visual interpretation of colored lines, with no mention of computational analysis, algorithms, or machine learning.
No
The device is a diagnostic tool for pregnancy detection, not a treatment or therapeutic intervention.
Yes
The device is described as an "immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine, as an aid for the early detection of pregnancy." This directly indicates its use in diagnosing pregnancy, which is a diagnostic purpose.
No
The device description clearly outlines a physical test strip that utilizes chemical reactions and capillary action to detect hCG. This involves hardware components (the strip itself, membrane, antibodies, etc.) and is not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "qualitative detection of human chorionic gonadotropin (hCG) in urine, as an aid for the early detection of pregnancy." This is a test performed on a biological sample (urine) outside of the body to provide information about a physiological state (pregnancy).
- Device Description: The description details a "rapid chromatographic immunoassay" that utilizes antibodies to detect a substance (hCG) in a biological specimen (urine). This is a common method used in IVD tests.
- Performance Studies: The performance studies involve testing urine specimens and comparing the results to another commercially available urine test. This is typical for validating the performance of an IVD.
The definition of an In Vitro Diagnostic (IVD) is a medical device that is used to perform tests on samples such as blood, urine, or tissue, taken from the human body, to detect diseases, conditions, or infections. The ACON™ One Step Pregnancy Test Strip fits this definition perfectly.
N/A
Intended Use / Indications for Use
ACON™ One Step Pregnancy Test Strip (Urine) is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine, as an aid for the early detection of pregnancy. This test is for professional use.
Product codes
JHI
Device Description
ACON™ One Step Pregnancy Test Strip (Urine) is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine, as an aid for the early detection of pregnancy. The test utilizes a combination of monoclonal and polyclonal antibodies to selectively detect elevated levels of hCG. The assay is conducted by immersing the test strip in the urine sample and observing for the formation of colored lines. The specimen migrates via capillary action along the membrane to react with the colored conjugate. Positive specimens react with the specific antibody-hCG-colored conjugate and form a colored line in the Test Area of the membrane. Absence of this colored line suggests a negative result. To serve as a procedural control, a colored line in the Control Area will always appear regardless of the presence or absence of hCG.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A multi-center clinical evaluation was conducted comparing the results obtained using ACON™ One Step Pregnancy Test Strip (Urine) and another commercially available urine membrane test. The study included 150 urine specimens tested with both assays.
Summary of Performance Studies
A multi-center clinical evaluation was conducted comparing the results obtained using ACON™ One Step Pregnancy Test Strip (Urine) and another commercially available urine membrane test. The study included 150 urine specimens tested with both assays. ACON™ One Step Pregnancy Test Strip (Urine) showed a 100% concordance with the other commercially available test. ACON™ One Step Pregnancy Test Strip (Urine) detects hCG concentrations of 25 mIU/ml and greater. The test has been standardized to the World Health Organization Third International Standard. The addition of hLH (300mUl/ml, hFSH (1000 mIU/ml), and hTSH (1000μIUml) to negative and positive serum and urine specimens showed no cross-reactivity.
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
DEC - 1 1996
"Summary of Safety & Effectiveness"
ACON™ One Step Pregnancy Test Strip (Urine) is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine, as an aid for the early detection of pregnancy. The test utilizes a combination of monoclonal and polyclonal antibodies to selectively detect elevated levels of hCG. The assay is conducted by immersing the test strip in the urine sample and observing for the formation of colored lines. The specimen migrates via capillary action along the membrane to react with the colored conjugate. Positive specimens react with the specific antibody-hCG-colored conjugate and form a colored line in the Test Area of the membrane. Absence of this colored line suggests a negative result. To serve as a procedural control, a colored line in the Control Area will always appear regardless of the presence or absence of hCG.
A multi-center clinical evaluation was conducted comparing the results obtained using ACON™ One Step Pregnancy Test Strip (Urine) and another commercially available urine membrane test. The study included 150 urine specimens tested with both assays. The following results were found:
| | Positive
Results | Negative
Results |
|--------------------------------------------------|---------------------|---------------------|
| ACON™ One Step
Commercially
Available Test | 78 | 72 |
| | 78 | 72 |
ACON™ One Step Pregnancy Test Strip (Urine) showed a 100% concordance with the other commercially available test.
ACON™ One Step Pregnancy Test Strip (Urine) detects hCG concentrations of 25 mIU/ml and greater. The test has been standardized to the World Health Organization Third International Standard. The addition of hLH (300mUl/ml, hFSH (1000 mIU/ml), and hTSH (1000μIUml) to negative and positive serum and urine specimens showed no cross-reactivity.
Ara C. R. York
Nora C.R. ACON Laboratories, Inc. 11175 Flintkote, Avenue, Suite F San Diego, CA 92121 UDA
9/23/99
Date
Premarket Notification 510(k) Number
1
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles three abstract human figures or birds in flight, arranged in a row.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
DEC - 1 1999
Ms. Nora C.R. York Regulatory Affairs Manager Acon Laboratories, Inc. 11175 Flintkote Avenue Suite F San Diego. California 92121
K993203 Re:
Trade Name: Acon™ One Step Pregnancy Test Strip (Urine) Regulatory Class: II Product Code: JHI Dated: September 23, 1999 Received: September 24, 1999
Dear Ms. York:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrlv/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Indications For Use
Registration 510(k)Number:
Device Name: ACON™ One Step Pregnancy Test Strip (Urine)
"Indications For Use" - ACON™ One Step Pregnancy Test Strip (Urine) is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in urine, as an aid for the early detection of pregnancy. This test is for professional use.
(Please do not write below this point)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(per 21 CFR 801.109)
Over-The-Counter Use Or